Clinical Trials Logo

Carcinoma, Adenosquamous clinical trials

View clinical trials related to Carcinoma, Adenosquamous.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05216120 Withdrawn - Pancreas Cancer Clinical Trials

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Start date: June 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this research is to determine the benefit of pemigatinib in patients with advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.

NCT ID: NCT03834571 Withdrawn - HIV Infection Clinical Trials

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

Start date: May 31, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well standard chemotherapy and radiation therapy given with or without paclitaxel and carboplatin work in treating human immunodeficiency virus (HIV)-positive women with cervical cancer that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin work in different ways to stop the growth of tumor cells. They may either kill the cancer cells by stopping them from dividing, or by stopping them from spreading. Radiation therapy to the pelvis destroys potential cancer cells in the pelvic area and significantly reduces the risk of tumor recurrence in the pelvic area. It is not yet known if giving chemotherapy and radiation therapy with paclitaxel and carboplatin afterward may work better than than just chemotherapy and radiation therapy in treating HIV-positive patients with advanced cervical cancer.

NCT ID: NCT01301612 Withdrawn - Carcinoma Clinical Trials

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Start date: January 2011
Phase: Phase 2
Study type: Interventional

The primary study objective will be to assess the efficacy of the combination of radiation therapy with nimotuzumab and cisplatin, as compared to the combination of radiation therapy plus cisplatin in the treatment of Uterine Cervical Carcinoma (UCC). The secondary study objectives will be safety and tolerability evaluations, to determine treatment feasibility and the interim efficacy evaluation according to other parameters routinely used in oncology.